Answers are grounded in this paper and cite their sources.
Cryopyrin-associated periodic syndrome (CAPS) encompasses a ‘continuum’ of features caused by gain-of-function variants in NLRP3, ranging from mild familial cold autoinflammatory syndrome to severe neonatal-onset multisystem inflammatory disease. Although NLRP3 variants are traditionally considered germline alterations, increasing evidence has revealed that post-zygotic somatic variants may account for a substantial proportion of patients with CAPS-like phenotypes, particularly among individuals with late-onset atypical or complex manifestations. Importantly, somatic NLRP3 variants are associated with wide clinical heterogeneity, which cannot be explained solely by variant allele frequency. Timing of the mutational event, proportion and distribution of affected cells, lineage restriction, variant-specific functional effects, and subsequent clonal dynamics may all contribute to protean clinical phenotypes. Somatic mosaicism has been identified across the classical CAPS entities and increasingly in patients presenting with nonclassical or nuanced autoinflammatory sceneries with onset in adulthood. Recent longitudinal studies further suggest that mosaic clones may display distinct patterns of stability or expansion, including myeloid-restricted clonal evolution. In this narrative review, we summarize the current evidence on both molecular and clinical consequences of somatic NLRP3 variants, with particular emphasis to genotype–phenotype relationships (when present), cellular distribution, clonal dynamics, diagnostic challenges, and therapeutic implications. Understanding these mechanisms may refine the classification of NLRP3-associated diseases and improve management strategies for patients with CAPS displaying complex unexplained or treatment-refractory clinical expression.
No takes yet. Share an insight, caveat, or question.
Rosa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: